Abstracts tagged "autoimmune diseases"

Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0095 • ACR Convergence 2024
Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Minjung Kim¹, Cecilia Stumpf², Hadijat Makinde¹, Mohammad Khan¹, Vanessa Rodriguez², Tyler Therron², Jeremy Tilstra³, Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³University of Pittsburgh, Pittsburgh, PA, ⁴Northwestern University, Skokie, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
Abstract Number: 0255 • ACR Convergence 2024
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Razan Al Yaarubi¹, Amanda Steiman¹ and Earl Silverman², ¹University of Toronto, Toronto, ON, Canada, ²Silverman, Toronto, ON, Canada
Background/Purpose: Infections are a leading cause of morbidity and mortality in patients with childhood-onset systemic lupus erythematosus (cSLE). Vaccination is a powerful tool to prevent…
Abstract Number: 0318 • ACR Convergence 2024
The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Chi Chi Lau¹ and Ayesha Arif², ¹University of Vermont Medical Center, colchester, VT, ²University of Vermont Medical Center, Essex Junction, VT
Background/Purpose: A positive (+)ANA titer is a common reason for Rheumatology consultation, yet the ANA is a nonspecific, non-diagnostic, lab test that is positive in…
Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Sagrario Corrales¹, Carlos Perez-Sanchez¹, Laura Muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera³, María Lourdes Ladehesa-Pineda⁵, Pilar Font¹, Ismael Sánchez Pareja¹, María Carmen Ábalos-Aguilera⁶, Desiree Ruiz-Vilchez⁴, Christian Merlo⁷, Mª Angeles Aguirre-Zamorano⁸, Tomás Cerdó¹, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁵, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Hospital Reina Sofía, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…
Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Leonie Middelink¹, Annemarie Kip², Maarten van der Linden³, Sangeeta Kumari², Stephanie van Dalen², Josephine Stein⁴, Tirza Bruurmijn², Martyn Foster⁵, Peter van Zandvoort², Patrick Round², Eric Meldrum², Helmuth van Es² and Renato Chirivi², ¹Citryll, Oss, Noord-Brabant, Netherlands, ²Citryll BV, Oss, Noord-Brabant, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴Citryll BV, Oss, Noord-Holland, Netherlands, ⁵Experimental Pathology Consultancy, Benfleet, United Kingdom
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…
Abstract Number: 0845 • ACR Convergence 2024
Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Thomas Riley¹, Kristin Wipfler², Katherine Wysham³, Michael George⁴, Kaleb Michaud⁵ and Joshua Baker⁴, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…
Abstract Number: 0939 • ACR Convergence 2024
A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…
Abstract Number: 1105 • ACR Convergence 2024
PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor M. Mora-Cuesta³, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁴, José M. Cifrián⁵, Ricardo Blanco-Alonso⁶ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the main causes of mortality in patients with autoimmune diseases (ADs) [1]. The early diagnosis of AD-ILD+…
Abstract Number: 1295 • ACR Convergence 2024
A Qualitative Survey of Internal Medicine Residents’ Understanding of Appropriate ANA Testing: An 11-Year Update Since the ‘Choosing Wisely’ Campaign
Arushika Yedla¹, Wei Tang², Jaspreet Bhatti², Kyu-In Lee³ and James Miceli³, ¹Westchester Medical Center, White Plains, NY, ²Westchester Medical Center, Valhalla, ³Westchester Medical Center, Valhalla, NY
Background/Purpose: ANA testing is recommended when there is a reasonable clinical suspicion for systemic autoimmune disease. Testing in the setting of low pre-test probability, however,…
Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…
Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Lily BRUYERE¹, Anne-Claire DUCHEZ², Martin KILLIAN³ and Stéphane PAUL⁴, ¹université jean-monnet, saint-etienne, ²EFS, saint-etienne, ³chu Saint-Etienne, saint-etienne, ⁴CIRI, Saint Etienne, France
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…
Abstract Number: 1784 • ACR Convergence 2024
T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE
Athanasios Sachinidis¹, Maria Trachana², Anna Taparkou², George Gavriilidis³, Vasileios Vasileiou³, Sofoklis Keisaris³, Panayotis Verginis⁴, Christina Adamichou⁵, Dimitrios Boumpas⁶ and Alexandros Garyfallos², ¹School of Medicine, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece, ²Ippokrateio General Hospital Thessaloniki, Thessaloniki, Greece, ³Centre for Research and Technology Hellas, Thessaloniki, Greece, ⁴Medical School, University of Crete, Heraklion, Crete, Greece, ⁵IPPOKRATEION HOSPITAL OF THESSALONIKI, Athens, Greece, ⁶4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: T-bet+ B cells, known as age-associated B cells (ABCs) and/or double-negative B cells (DN), expand in various autoimmune diseases. This study aimed to clarify…
Abstract Number: 1857 • ACR Convergence 2024
Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations
Brooke Huisman¹, Daniel Michelson¹, Sara Rubin¹, Katherine Kohlsaat², Wilson Gomarga², Yuan Fang¹, Ji Myung Lee², Pedro del Nido², Meena Nathan², Christophe Benoist¹, Leonard Zon² and Diane Mathis¹, ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Thymic mimetic cells are molecular hybrids between medullary thymic epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T…
Abstract Number: 1982 • ACR Convergence 2024
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Sarah Ifteqar¹, Mallak Zatreh², Aatif Syed¹, Xiangni Wu³, Asad Kabir⁴, John Foxworth⁵ and AMR EDREES⁶, ¹University of Missouri Kansas City, Kansas City, MO, ²3. Hutchinson Regional Medical Center, Hutchinson, Kansas, USA, Kansas City, ³UMKC, KANSAS CITY, MO, ⁴5. Pulmonary Critical Care, Mosaic Life Care Health System, St. Joseph, Missouri, USA, Kansas City, ⁵2. Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA, Kansas City, ⁶UMKC, Overland Park, KS
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus affect 3-5% of Americans and causes significant morbidity due to chronic…

« Previous Page
1
…
8
9
10
11
12
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].